Passage Bio, Inc. (PASG)

Market Cap	70.24M
Revenue (ttm)	n/a
Net Income (ttm)	-102.06M
Shares Out	61.61M
EPS (ttm)	-1.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,740
Open	1.150
Previous Close	1.150
Day's Range	1.123 - 1.190
52-Week Range	0.575 - 1.790
Beta	1.30
Analysts	Strong Buy
Price Target	9.33 (+718.42%)
Earnings Date	May 9, 2024

About PASG

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 28, 2020
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: PASG

Analyst Forecast

According to 3 analysts, the average rating for PASG stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 718.42% from the latest price.

Price Target

$9.33

(718.42% upside)

Analyst Consensus: Strong Buy